Trump Says Iran Ceasefire Near Collapse as Oil Prices Surge 
Trump Rejects Iran Proposal as Strait of Hormuz Crisis Pushes Oil Prices Higher 
Trump-Iran Tensions Keep Oil Prices Elevated Amid Hormuz Supply Fears 
Rubio Discusses Iran Crisis and Strait of Hormuz Disruptions With UK and Australia 
South Korea Central Bank Signals Inflation Concerns as Oil Prices Surge 
Norway Core Inflation Hits 3.2% in April, Fueling Interest Rate Hike Expectations 
US Stock Futures Slip as Trump Rejects Iran Peace Proposal Amid Rising Middle East Tensions 
Asian Stocks Slip as Korea’s KOSPI Tumbles Amid Iran Conflict and Chip Sector Profit-Taking 
Dollar Rises as Strait of Hormuz Crisis Pushes Oil Prices Higher 
US, Japan Reaffirm Strong Currency Coordination Amid Yen Volatility 
Trump-Xi China Summit 2026: Trade Tensions, Taiwan, and Iran Take Center Stage 
China Inflation Jumps as Iran Conflict Drives Energy Costs Higher 
Indian Stock Market Drops as Iran Conflict Fuels Oil Price and Inflation Fears 
US Inflation Expected to Rise Again in April as Fed Signals Higher Interest Rates 
Trump Administration Seeks Court Pause to Reinstate 10% Global Tariffs 
Goldman Sachs Delays Fed Rate Cut Forecast to 2026 Amid Rising Inflation Concerns 
Dollar Gains on Safe-Haven Demand as Iran Tensions and Inflation Data Loom 
China’s WuXi AppTec has signed an agreement to sell its gene therapy manufacturing arm, WuXi Advanced Therapies, to U.S.-based Altaris LLC, following mounting restrictions on Chinese firms in the United States over national security concerns. The deal also includes Oxford Genetics in the UK.
WuXi AppTec Sells Gene Therapy Unit Amid US Restrictions
The Chinese company WuXi AppTec announced on Tuesday that its subsidiaries have inked a contract with the private equity firm Altaris LLC, which is based in the United States, for the sale of its cell and gene therapy manufacturing unit, WuXi Advanced Therapies, for an amount that has not been disclosed.
Due to worries regarding national security, the corporation, along with other Chinese businesses, has been at the focus of new regulations that have been enacted in the United States with the intention of restricting their businesses in the United States, Investing.com shares.
US Legislation Targets Chinese Companies Over National Security Concerns
In September, the House of Representatives of the United States of America enacted a bill that would bar the federal government from entering into contracts with specified companies and those that do business with those companies.
The laws are intended to protect the personal health and genetic information of Americans from foreign adversaries.
Shift in US Pharma and Biotech Supply Chains
Additionally, they intend to encourage pharmaceutical and biotechnology businesses in the United States to reduce their reliance on China for a variety of activities, including the manufacturing of medicinal ingredients and early research.
The United Kingdom-based operating company of the WuXi ATU business, Oxford Genetics, will be sold to Altaris LLC, according to a statement made by WuXi.
Altaris declined to comment further than the information that was provided, while WuXi AppTec did not react to a request for comment made by Reuters by the company.
